Signal Transduction and Targeted Therapy

Article	Citations
Greasy hair against obesity	1807
Cocktails of defined chemical compounds: sufficient to induce totipotency in embryonic stem cells	1618
Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection	1490
Somatic mutant clone screening: scan for novel NASH target genes in mouse liver	1231
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster	1068
Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE	1067
Moving towards precision psychiatry: the hard nut of depression	996
Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis	868
Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics	857
Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure	806
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages	801
Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis	769
Comparing acute versus AIDS ART initiation on HIV-1 integration sites and clonal expansion	753
Correction: Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine	748
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates	747
Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry	743
A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease	698
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	694
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma	686
Sensory neurons: unveiling the symphony of wound healing	684
Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells	680
CD4 T cell contact drives macrophage cell cycle G0-G1 transition	679
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance	673
PD-1 and LAG-3: synergistic fostering of T cell exhaustion	672
Animal models for COVID-19: advances, gaps and perspectives	670

Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study	650
Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness	642
Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis	591
Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications	586
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study	578
Signal pathways of melanoma and targeted therapy	555
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders	541
Identification of glutamine as a potential therapeutic target in dry eye disease	531
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT	525
Massively parallel interrogation of human functional variants modulating cancer immunosurveillance	521
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects	509
Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms	505
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration	505
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study	503
S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis	483
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases	467
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies	467
Phototherapy in cancer treatment: strategies and challenges	466
Neutrophil extracellular traps in homeostasis and disease	465
Correction: The Hippo signalling pathway and its implications in human health and diseases	458
A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer	454
Age-induced changes in lung microenvironment: from melanoma dormancy to outgrowth	453
Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy	450
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors	440
Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression	429
Impact of mechanical circulatory support and immunomodulation therapy on outcome of patients with fulminant myocarditis: Chinese registry of fulminant myocarditis	421
Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair	412
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy	406
Top(ological-operon) secret behind the long-range transcriptional coupling	401
Omicron spike protein: a clue for viral entry and immune evasion	401
Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters	400
Beyond borders: the choroid plexus-immune communication during neuroinflammation	399
SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes	398
From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism	394
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination	390
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma	376
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies	374
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy	372
Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss	370
Harnessing innate immune pathways for therapeutic advancement in cancer	369
PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron	355
The RING finger protein family in health and disease	347
Platelets and diseases: signal transduction and advances in targeted therapy	330
Escaping alveolar macrophage endosomal retention explains massive expansion of SARS-CoV-2 delta variant	329
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN	329
Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver	327
Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis	323
Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects	322
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	319
Microbiota in health and diseases	310

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	309
Base editing: a promising tool to rescue spinal muscular atrophy	304
Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes	295
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine	292
Predicting the next move: tracking the complexity of lung cancer evolution and metastasis	290
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape	285
Mind-body control: a new perspective on motor neuron function	283
Persistent SARS-CoV-2 infection in asymptomatic young adults	280
Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity	277
DNA framework signal amplification platform-based high-throughput systemic immune monitoring	276
Metaplastic epithelial cells: origination from stem cells and promotion of intestinal inflammation	275
sRAGE alleviates SARS-CoV-2-induced pneumonia in hamster	272
Nascent mRNA damage: depot and disposal	271
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury	267
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations	265
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors	263
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis	258
Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease	256
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants	255
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression	248
Mitochondrial heterogeneity in diseases	247
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus	246
High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming	246
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread	243
STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation	243
RUNX1 promotes mitophagy and alleviates pulmonary inflammation during acute lung injury	241
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies	239
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization	237
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer	233
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia	233
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases	231
Linking B cell metabolism to immune regulation: the neurotransmitter GABA	230
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer	230
Molecular insights of exercise therapy in disease prevention and treatment	229
CNTNAP2 intracellular domain (CICD) generated by γ-secretase cleavage improves autism-related behaviors	228
Lactate metabolism in human health and disease	227
Targeting PI3K/Akt signal transduction for cancer therapy	225
Small molecules in the treatment of COVID-19	222
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection	219
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	219
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	218
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	218
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	216
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy	215
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors	210
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy	209
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities	208
A new treatment for sarcoma extracted from combination of miRNA deregulation and gene association rules	200
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy	200
Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control	200
Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice	193
Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma	193
Single-cell genomics: the human biomolecular and cell atlases	192
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants	191
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function	190
RNA interfering machinery: new insight into the Dicer-2 complexes in the dsRNA-processing cycle	190
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics	189
C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness	189
Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia	188
Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study	186
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation	184
Stem loop binding protein promotes SARS-CoV-2 replication via -1 programmed ribosomal frameshifting	183
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection	182
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus	182
Back to pluripotency: fully chemically induced reboot of human somatic cells	181
Post-fast refeeding: rise of intestinal stemness and mutagen-induced cancer risk through polyamine metabolism	181
Combination therapy for HCC: from CRISPR screening to the design of clinical therapies	178
ELANE: an emerging lane to selective anticancer therapy	176
Current landscape of innovative drug development and regulatory support in China	175
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1	175
Programmable synthetic receptors: the next-generation of cell and gene therapies	173
Mutually exclusive epigenetic modification on SIX6 with hypermethylation for precancerous stage and metastasis emergence tracing	169
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication	168
Glioblastoma at the crossroads: current understanding and future therapeutic horizons	167
Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells	167
Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer	166
The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2	163
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling	163
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors	162
Signaling pathways and targeted therapies for psoriasis	162

RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation	159
mRNA-based therapeutics: powerful and versatile tools to combat diseases	157
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration	156
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	156
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer	152
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer	152
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition	151
Phenotypic characteristics and T cell receptor properties in melanoma: deciphering the correlation at single-cell resolution	151
Deconstructing the intra-tumor subclonal heterogeneity of lung synchronous ground-glass nodules using whole-genome sequencing	151
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance	149
Time’s up: mutation rate and lifespan	149
Adhesion G protein-coupled receptor latrophilin 1 (ADGRL1): a novel regulator of glucose and energy homeostasis	147
Activated STING: an ion channel to trigger non-interferon-related functions	146
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis	145
Balancing memory in sleep: firing barrages as a circuit breaker for reactivation	143
I prostanoid receptor activation attenuates pressure overload-induced cardiac hypertrophy by enhancing glucose oxidation	143
Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells	141
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial	140
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein	140
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial	139
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes	139
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis	137
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts	137
Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like	136
An anti-tumor coup: TIM3 ablation activates the immune arsenal	136
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications	133
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells	133
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial	132
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity	130
LIX1-like protein drives hepatic stellate cell activation to promote liver fibrosis by regulation of chemokine mRNA stability	129
Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone	129
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape	128
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	127
Bat organoid platform: revolutionizing zoonotic virus research and pandemic preparedness	126
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation	125
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates	123
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression	123
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study	122
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs	120
The biological applications of DNA nanomaterials: current challenges and future directions	120
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies	120
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study	119
Artificial intelligence in cancer target identification and drug discovery	118
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	116
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis	116
Redox regulation: mechanisms, biology and therapeutic targets in diseases	116
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism	115
Targeted protein degradation: advances in drug discovery and clinical practice	114
Intervening pyruvate carboxylase stunts tumor growth by strengthening anti-tumor actions of tumor-associated macrophages	114
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines	114
Arterial stiffness and vascular aging: mechanisms, prevention, and therapy	113
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	113
Signaling pathways in obesity: mechanisms and therapeutic interventions	112
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	112
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential	111
CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection	110
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomiz	110
Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic	110
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome	109
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial	108
Hypocretin neuron hyperexcitability in the hypothalamus: a newly discovered culprit in aging-related sleep impairment	107
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial	107
PARP1-DNA co-condensation: the driver of broken DNA repair	107
Human genetic basis of coronavirus disease 2019	106
A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol	105
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies	105
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial	105
The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis	103
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal c	102
IL-17 signaling in skin repair: safeguarding metabolic adaptation of wound epithelial cells	102
GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer	101
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial	101
The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation	100
A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver	99
Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes	98
Correction: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism	98
Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern	98
A pan-cancer fingerprint: common molecular denominators of the human tumor microenvironment	98
Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism	96
Human cross-tissue cell atlases: unprecedented resources towards systematic understanding of physiology and diseases	95
Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure	95
Artificial intelligence propels lung cancer screening: innovations and the challenges of explainability and reproducibility	95
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression	94
Mutation-independent gene knock-in therapy targeting 5′UTR for autosomal dominant retinitis pigmentosa	93
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study	93
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation	93
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes	92
DRC3 is an assembly adapter of the nexin-dynein regulatory complex functional components during spermatogenesis in humans and mice	92
SLC7A11: a new regulator in diabetic wound healing	92
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches	92
Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1	91
CAR-T cell therapy for cancer: current challenges and future directions	90
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder	90
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy	89
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection	86